Anti-CEA antibodies were used for radio-immunotherapy in an established LS174T colonic xenograft in nude mice. A single IV dose of either I3'I-PK4S (polyclonal) or -A5B7 (monoclonal) antibody produced tumour regression, and sig- nificantly delayed subsequent tumour growth. Administration of a cleari
The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-cea antibody in a human colonic tumor xenograft model
β Scribed by R. Barbara Pedley; Roger Dale; Joan A. Boden; Richard H. J. Begent; Pat A. Keep; Alan J. Green
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- French
- Weight
- 651 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Radioimmunotherapy in humans is limited by toxicity to normal tissues, caused by circulating radio-antibody. Second antibody directed against the first (anti-tumor) antibody accelerates clearance of first antibody from normal tissues, and may thus improve the therapeutic ratio. The effect of second antibody both on anti-tumor antibody distribution and on tumor and normal tissue radiation doses, has been investigated in nude mice bearing colonic tumor xenografts. Second antibody, gfven either 6 or 24 hr after the first, rapidly cleared circulating activity and reduced the calculated radiation dose to all tissues except the spleen, where it rose by I I and 43% 7 I %, while that to the tumor was reduced by 8 I d a n d 58%,
π SIMILAR VOLUMES
The magnitude and kinetics of tumor uptake of a monoclonal antibody (MAb) directed against carcinoembryonic antigen (CEA) in the GW-39 human colorectal cancer xenograft differ according to the animal used (nude mouse or hamster) and the site of implantation of the tumor within the animal (cheek pouc
## Background: Previous studies have shown an upregulation of matrix metalloproteinases (mmps) in intestinal tissue of patients with inflammatory bowel disease (ibd) and significant clinical improvement after administration of the anti-tnf-a antibody infliximab. the aims of our study were to determ